← Analyst Upside
AU · rank #3 · 2026-10-21
VIRP
PARIS · EUR · $3.25B (USD)
SignalStrong Buy4.7strength 4.7 / 10
verdict · PROCEED
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.763 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.21 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 4 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $412.75 | +19.6% |
| Momentum acceleration 3-month minus 12-month momentum. | +3.88% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.63 |
| Gross margin TTM | +67.2% |
| 52w high | $387.79 |
| Market cap (USD) | $3.25B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Virbac SA is a global veterinary pharmaceutical company that manufactures and markets specialty companion-animal and livestock health products, vaccines, and diagnostic treatments.
Rationale
Upward EPS revisions across 100% of covering analysts and 19.6% implied upside are reinforced by 9M 2026 organic revenue growth tracking at the top end of full-year guidance.
Material risks
- 1Regulatory hurdles and supply constraints in North America and Western Europe could interrupt product availability and impair regional margin expansion.
- 2Execution risk associated with €125 million in planned industrial capital expenditure and the complex manufacturing transfer of key products like Suprelorin.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.
OpenAI
Proceed
Claude
Caution
Gemini
Proceed